Antimicrobial sensitisers: Gatekeepers to avoid the development of multidrug-resistant bacteria

  26 March 2024

Multidrug-resistant bacteria’s resistance to antibiotics necessitates the development of new antibacterial agents, but high costs and timeframes limit their development. The concept of “antibiotic adjuvant” has limited drug development speed. This review article introduces the concept of non-self-antimicrobial sensitisers (NSAS), distinguishing it from antibiotic adjuvants. It discusses scientific methods to restore bacterial sensitivity to antibiotics, sources, and action mechanisms of existing NSAS, guiding further research.

Author(s): Hanfei Wang et al
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Your Biweekly Source for Global AMR Insights!

Stay informed with the essential newsletter that brings together all the latest One Health news on antimicrobial resistance. Delivered straight to your inbox every two weeks, AMR NEWS provides a curated selection of international insights, key publications, and the latest updates in the fight against AMR.

Don’t miss out on staying ahead in the global AMR movement—subscribe now!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed